For example, the use of a combination therapy consisting of an ALDH inhibitor (disulfiram) and cisplatin-based chemotherapy resulted in an improvement of survival for advanced NSCLC patients, indirectly suggesting that ALDH inhibition may counter drug resistance [66]. The gene discussed is LDHA; the disease is non-small cell lung carcinoma.